Paraneoplastic Pemphigus



Anhalt et al[1] first described paraneoplastic pemphigus in 1990. The authors reported 5 patients with underlying neoplasms who developed oral erosions and bullous skin eruptions. Skin biopsy samples showed both suprabasal acantholysis and interface dermatitis. Direct immunofluorescence (DIF) testing and indirect immunofluorescence (IDIF) testing revealed intraepidermal intercellular staining with immunoglobulin G (IgG); DIF testing also revealed deposition of complement at the dermoepidermal junction (see the image below). By immunoprecipitation, target antigens were identified from skin extracts with molecular weights of 250, 230, 210, and 190 kd. Since then, many patients with paraneoplastic pemphigus have been reported, and patients previously believed to have other diseases have been retrospectively diagnosed.

View Image

Direct immunofluorescence microscopy performed on epithelial biopsy specimen obtained from a patient with pemphigus vulgaris detects immunoglobulin G ....

A summary of the original criteria for the diagnosis of paraneoplastic pemphigus includes the following:

Because not all patients demonstrate these original criteria, Anhalt[2] has proposed the following new, minimal criteria for the diagnosis of paraneoplastic pemphigus:

Note, however, that while a tumor is essential in the diagnosis, patients with tumors other than lymphoproliferative neoplasms can develop paraneoplastic pemphigus. These include thymoma, sarcoma, and lung carcinoma.


Paraneoplastic pemphigus (PNP) is an autoimmune disorder initiated by an underlying neoplasm. Tumor antigens are hypothesized to evoke both a humoral and a cellular immune response that leads to blistering in mucosa and other epithelia. Affected organ systems include the integument, respiratory tract, and gastrointestinal tract. Most patients have had an associated malignancy, often a lymphoproliferative disorder, but it has also been reported to occur in association with benign tumors.[3] Associated neoplasms include non-Hodgkin lymphoma, chronic lymphocytic leukemia, Castleman disease, thymoma, Waldenström macroglobulinemia, Hodgkin lymphoma, various carcinomas, sarcomas, and malignant melanoma.[4]

Passive transfer of paraneoplastic pemphigus sera causes blistering in neonatal mice, proving that the antibodies present are pathogenic.[1] Paraneoplastic pemphigus patients exhibit many different autoantibodies to proteins of the plakin family, an intracellular component of desmosomes and hemidesmosomes, including envoplakin (210-kd), periplakin (190-kd), bullous pemphigoid antigen I (230-kd), desmoplakin I (250-kd), desmoplakin II (210-kd), plectin (500-kd), and alpha2-macroglobulin-like–1 (170-kd). They can also exhibit antibodies to antigens associated with pemphigus vulgaris (desmoglein 3, 130-kd) and pemphigus foliaceus (desmoglein 1, 160-kd), as well as several others.



Paraneoplastic pemphigus is often fatal, especially when associated with malignancy. Mortality rates approach 90%. Causes of death include the evolution of the underlying neoplasm, sepsis with resultant multiorgan failure, and respiratory failure due to the direct effects of the disease on the respiratory tract epithelium. The latter is being increasingly recognized, and pulmonary involvement has been found to occur in approximately 30-40% of patients. The susceptibility to infection caused by the loss of skin integrity is exacerbated by the potent immunosuppressive medications used to treat the condition.

Patients with paraneoplastic pemphigus and long-term survival have been described. Those whose underlying neoplasm is benign, such as in Castleman disease and thymoma, tend to have a better prognosis.

A recent study on 53 patients with paraneoplastic pemphigus found a mortality rate of 68%. The authors surmise that this was lower than other reported rates because of the inclusion of patients with only moderate, as opposed to severe, disease. Patients with erythema multiforme–like lesions and keratinocyte necrosis on biopsy, especially when associated with severe skin or mucosal involvement, tended to have a worse prognosis.


No racial predilection is apparent for paraneoplastic pemphigus.


Males and females are affected equally by paraneoplastic pemphigus.


Paraneoplastic pemphigus has been reported in patients aged 7-83 years. It typically affects patients aged 45-70 years, but it can also be seen in children and adolescents.[4]


Paraneoplastic pemphigus is usually associated with malignancy, although it can occur in association with benign neoplasms. The most common malignancy associated with paraneoplastic pemphigus is non-Hodgkin lymphoma.[5, 6, 7] Other associated malignancies and conditions include chronic lymphocytic leukemia, Castleman disease,[8, 9, 10, 11] Waldenström macroglobulinemia,[12] thymoma,[9, 13] sarcoma,[13] , lung carcinoma, and malignant melanoma.[4] It has recently been reported in a patient with HIV disease who was found to have intra-abdominal diffuse B-cell lymphoma.[14]

An association reported in 2009 is with systemic mastocytosis,[15] and an atypical case associated with endometrial carcinoma lacking mucosal involvement has been reported.[16] Paraneoplastic pemphigus can coexist with bullous pemphigoid[17] and has been reported to "shift" to pemphigus vulgaris.[18]

Also see Non-Hodgkin Lymphoma (pediatric focus), Chronic Lymphocytic Leukemia, Waldenstrom Hypergammaglobulinemia, and Thymoma

Patients present with painful oral erosions, often accompanied by a generalized cutaneous eruption. Oral erosions occur early and typically are severe, often involving the lateral tongue and vermilion. The eruption can assume a wide variety of morphologies. A classification system has been suggested, dividing lesions into pemphiguslike, pemphigoidlike, erythema multiforme–like, graft versus host disease–like, and lichen planus–like. Additionally, some patients report pruritus or pain. Cases without mucosal involvement have been reported, especially with the lichen planus –like variant, although these patients lacked autoantibodies.[19]


Mucosal findings

The earliest and most constant clinical finding in paraneoplastic pemphigus is painful oral erosions. Of those patients who present with a skin eruption, all go on to develop mucositis at some point during the course of the disease. Some patients only experience oral lesions.

The erosions of paraneoplastic pemphigus can occur anywhere in the mouth, including the buccal, labial, gingival, and lingual mucosae. All surfaces of the oropharynx can be affected. Erosions and subsequent crusting on the vermilion of the lips are typical and similar to that seen in persons with Stevens-Johnson syndrome. Genital mucosal surfaces can also be affected. Finally, nasal ulcers may cause epistaxis.

Cutaneous findings

The eruption of paraneoplastic pemphigus is highly variable. Patients may present with diffuse erythema, vesiculobullous lesions, papules, scaly plaques, exfoliative erythroderma, erosions, or ulcerations. The erythema can be macular, urticarial, or targetoid, and it may be polymorphous. Patients may initially present with erythema, and they may subsequently develop bullae and erosions.

Large areas of denudation with a positive Nikolsky sign can occur. Pustules have been reported. The papular lesions may resemble lichen planus, and the oral lesions may also be mistaken for lichen planus.[20] A single patient has been reported with a solitary, pemphigus vegetans–like lesion that arose in a previous bulla. The palms and the soles may be involved.

A recent study on prognostic factors of paraneoplastic pemphigus found the presence of erythema multiforme–like lesions heralded a worse prognosis, especially if there was keratinocyte necrosis on biopsy and severe skin or mucosal involvement.[21]

Extracutaneous findings

Biopsy-confirmed paraneoplastic pemphigus has been reported in the gastrointestinal tract and the respiratory tract mucosa. The latter has been increasingly recognized and is a significant cause of mortality. Pulmonary involvement manifests as obstructive lung disease and progresses to bronchiolitis obliterans and death. Despite its ominous significance, signs of pulmonary involvement are subtle. Patients develop dyspnea, yet chest radiograph findings are normal. Ocular involvement ranges from mild conjunctivitis to symblepharon with corneal scarring.[22]


The association of paraneoplastic pemphigus with malignancy is strong. Patients have had benign neoplasms, including thymoma and Castleman disease. Only a single patient without a tumor has met the diagnostic criteria, yet this patient had a rapid demise and may have died with an undiagnosed malignancy. Patients have developed paraneoplastic pemphigus while in remission of their malignancy, leading some authors to prefer the term neoplasia-induced pemphigus.[23]

Treatment of the underlying malignancy does not necessarily halt progression of the paraneoplastic pemphigus. Cases associated with benign neoplasms can improve dramatically when the tumor is resected, owing to the decreased production of autoantibodies.[4]

Circulating and tissue-bound antibodies in patients with paraneoplastic pemphigus are directed against a group of molecules with sequence homology and belonging to the plakin family. These molecules are found in the intracellular attachment plaques of desmosomes and hemidesmosomes, and they play a key role in intermediate filament attachment. However, the number of reported target antigens has increased over time and varies between patients. This variability likely accounts for the clinical heterogeneity of this disease. By immunoprecipitation, target antigens (in decreasing order of incidence) include desmoglein 3, desmoglein 1, envoplakin, periplakin, desmoplakin I, desmoplakin II, and bullous pemphigoid antigen I. Plectin and a recently identified 170-kd protein called alpha2-macroglobulin-like–1 have also been found.[24, 25]

How tumors induce autoantibodies to plakin proteins is not known. Tumor cells have been demonstrated to produce autoantibodies that react to epidermal proteins. Other postulates include (1) cross-reactivity of tumor antigens and epidermal antigens and (2) tumor production of plakin proteins that initiate an autoimmune response. Dysregulated cytokine production by tumor cells, specifically interleukin 6, contributing to the autoimmune process is another hypothesis. The concept of epitope spreading, with which patients develop antibodies to multiple structurally related and unrelated proteins, may explain the multitude of antibodies produced in association with this disease.

Laboratory Studies

The evaluation of patients suspected of having paraneoplastic pemphigus includes obtaining samples by skin biopsy for routine microscopy and direct immunofluorescence (DIF) testing (see image below), followed by more sophisticated testing when indicated.

View Image

Direct immunofluorescence microscopy performed on epithelial biopsy specimen obtained from a patient with pemphigus vulgaris detects immunoglobulin G ....

Other Tests

DIF testing

Skin biopsy samples for DIF testing should be taken from noninvolved, perilesional skin. IgG, with or without complement, binds in an intercellular pattern within the epidermis. Immunoglobulin A (IgA) and immunoglobulin M (IgM) also may be detected. Staining can be diffuse or focal. Positive findings limited to adnexal structures have been described.[31]

Some patients have granular or linear deposition of complement, IgG, and/or IgM along the dermoepidermal junction. The combination of intercellular and subepidermal deposition of immunoreactants is a clue to the diagnosis of paraneoplastic pemphigus.

IDIF testing

IDIF testing is performed by using sera obtained from patients suspected of having paraneoplastic pemphigus and is a good screening test for this disease. Patients with high-titer antibodies exhibit both intercellular intraepidermal antibody deposition and deposition along the dermoepidermal junction. Patients with low titers only exhibit deposition intercellularly in a pattern identical to that of pemphigus vulgaris.

Because circulating antibodies that bind to the cell surface of stratified squamous epithelia are common to all forms of pemphigus, other substrates, such as rodent bladder, can be useful in distinguishing paraneoplastic pemphigus from pemphigus vulgaris or pemphigus foliaceus. Binding to rat bladder transitional epithelium is specific for circulating autoantibodies from patients with paraneoplastic pemphigus, with a specificity of 83%;[26] sensitivity ranges from 75-86% depending on the study.

Immunoprecipitation and immunoblotting

A recent study found that immunoprecipitation for antibodies against envoplakin and periplakin or alpha2-macroglobulin-like–1 is the most sensitive test for paraneoplastic pemphigus, although the latter can also be seen in toxic epidermal necrosis. Because this test is not always readily available, the authors also suggest that the combination of IDIF on rat bladder and immunoblotting may be easier and have similar sensitivity and specificity.[25]

Sensitivity and specificity

A recent study on 19 paraneoplastic pemphigus patients revealed the following sensitivities[25] :

Specificity ranged from 86-100%.

Histologic Findings

Vesicular lesions express the most characteristic histopathologic features. Oral and cutaneous lesions show variable epidermal necrosis, suprabasal acantholysis, dyskeratotic keratinocytes, vacuolar interface dermatitis, and lymphocytic exocytosis. Substantial inflammation can be present, even in early lesions.

Oral mucosal lesions show the greatest acantholysis, while some skin lesions may not have any acantholysis. Biopsy specimens of severe stomatitis may reveal only ulceration. When present, suprabasal acantholysis can result in clefts and tombstoning, which is the appearance of the basal cell layer below the cleft, and it can be indistinguishable from pemphigus vulgaris.

A distinctive feature of paraneoplastic pemphigus is dyskeratosis. Dyskeratosis is a constant feature, but the number of dyskeratotic keratinocytes is variable. Dyskeratotic keratinocytes are found at all levels in the epidermis, especially within the zones of acantholysis, and they can be found in cutaneous adnexa. The presence of dyskeratosis in a person with a suprabasal acantholytic bullous disorder is a clue to the presence of paraneoplastic pemphigus.

Interface dermatitis is a frequent finding in persons with paraneoplastic pemphigus, and it can be found both with and without acantholysis. Exocytosis of inflammatory cells into the epidermis is common, and the amount and degree are directly proportional to the degree of dyskeratosis. Satellite cell necrosis (a lymphocyte adjacent to a necrotic keratinocyte) can occur. Lesions showing marked vacuolar alteration are accompanied by melanophages in the papillary dermis.

Dermal changes include a superficial perivascular infiltrate of variable intensity, which is mostly composed of lymphocytes. The inflammation can sometimes be lichenoid, leading to a misdiagnosis of lichen planus. Papillary dermal edema is present in early lesions, whereas older lesions may exhibit mild dermal fibrosis.

Medical Care

Response to treatment paraneoplastic pemphigus is generally poor, especially for mucosal lesions. Initial care is aimed at treating superinfection, if present. Warm compresses, nonadherent wound dressings, and topical antibiotic ointment are helpful. Potent immunosuppressive agents are required to decrease blistering, but they are often ineffective. High-dose corticosteroids are first-line therapy for paraneoplastic pemphigus,[6] followed by steroid-sparing agents such as azathioprine, cyclosporine, and mycophenolate mofetil. In general, the skin lesions of paraneoplastic pemphigus are more responsive to therapy than mucosal lesions.[32]

Other therapeutic options for paraneoplastic pemphigus include plasmapheresis, immunophoresis, intravenous gammaglobulin,[33] and stem cell ablation therapy with high-dose cyclophosphamide[5] without stem cell rescue. Rituximab has been tried in several patients with mixed results.[34, 35] A review described the use of rituximab in paraneoplastic pemphigus. Treating the underlying malignancy may control autoantibody production, and intravenous gammaglobulin (IVIG) at the time of surgery may help prevent the development of bronchiolitis obliterans.

Surgical Care

For solid neoplasms, curative resection should be attempted when appropriate, but this does not halt disease progression, especially when malignant. If surgery results in decreased autoantibody production, the paraneoplastic pemphigus may improve. IVIG before, during, and after the surgery may block autoantibody released from the tumor.


Respiratory therapy may be beneficial when pulmonary involvement from paraneoplastic pemphigus causes respiratory insufficiency. Consultations from a pulmonary medicine specialist, an ophthalmologist, a gastroenterologist, and an otolaryngologist should be obtained when appropriate.

Medication Summary

The medications used to treat paraneoplastic pemphigus are potent immunosuppressive agents with numerous adverse effects. All patients taking these medications require periodic monitoring of laboratory values.

Prednisone (Deltasone, Orasone, Sterapred)

Clinical Context:  Affects all organ systems. On a cellular level, affects cell activation, replication, differentiation, and mobility. Net result is inhibition of immediate and delayed hypersensitivity. Suppression of antibody production requires higher doses than suppression of monocyte function.

Azathioprine (Imuran)

Clinical Context:  Often used in conjunction with prednisone for dermatologic purposes as a steroid-sparing agent. Purine analog with cytotoxic properties. Prodrug metabolized to 6-mercaptopurine. Inhibits RNA and DNA synthesis.

Cyclosporine (Sandimmune, Neoral)

Clinical Context:  Demonstrated to be helpful in a variety of skin disorders. Potent immunosuppressive agent most often used in organ transplantation. Diminishes production of autoantibodies and decreases resultant blistering and erosions. Acts by inhibiting T lymphocytes and lymphokine production.

Cyclophosphamide (Cytoxan, Neosar)

Clinical Context:  Recent reports suggest that cyclophosphamide in combination with systemic steroids is a useful regimen for paraneoplastic pemphigus. Has been used to ablate bone marrow, followed by stem cell rescue (peripheral blood stem cell transplantation). Chemically related to nitrogen mustards. As an alkylating agent, mechanism of action of active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells. Many PO/IV regimens exist, depending on disease being treated and status of patient.

Class Summary

These agents diminish the production of autoantibodies and decrease resultant blistering and erosions.

Immune globulins intravenous (Gammagard, Gamimune, Sandoglobulin)

Clinical Context:  Prepared from pooled plasma of 10,000-20,000 donors. Has many mechanisms of action, which are mediated by the Fc portion of IgG or the antigen-binding and variable regions of the F (ab') 2 portion. Has been used for dermatomyositis, pemphigus foliaceus, pemphigus vulgaris, epidermolysis bullosa acquisita, bullous pemphigoid, and herpes gestationis. High dose is needed for treatment of inflammatory and autoimmune disorders in comparison to replacement therapy for patients with deficiency.

Class Summary

IVIG is being increasingly used in high doses to treat many dermatologic inflammatory and autoimmune diseases, including autoimmune bullous disorders and dermatomyositis. However, few controlled trials exist, and it is costly and time consuming to administer. IVIG has been used as monotherapy and as adjunctive therapy.


The main complication of paraneoplastic pemphigus is impaired skin barrier function, which can lead to localized infection, sepsis, and death. Additionally, painful oral and pharyngeal ulceration can interfere with eating, which can compromise nutritional status. Finally, involvement of respiratory tract epithelium can lead to respiratory insufficiency due to bronchiolitis obliterans and can result in death.


In general, the prognosis of paraneoplastic pemphigus is poor; however, the prognosis is somewhat better when the disease is associated with benign tumors.

The mortality rate when associated with malignancy is estimated at 90%. Nearly all patients with the 2 most common associated tumors, non-Hodgkin lymphoma and chronic lymphocytic lymphoma, are dead of disease within 2 years of diagnosis. Note, however, that outcome does not parallel the course of the underlying malignancy. Both the presence of an underlying neoplasm and the adverse effects of the potent medications required to treat the disease add to both the morbidity and the mortality.

Paraneoplastic pemphigus is the only form of pemphigus that affects epithelia other than squamous. Involvement of respiratory mucosa, which manifests clinically as dyspnea with normal chest radiograph findings, is an ominous finding that progresses via an unknown mechanism to bronchiolitis obliterans. The most recent estimates are that approximately one third of the deaths from paraneoplastic pemphigus are due to pulmonary insufficiency.


Lynne J Goldberg, MD, Professor, Departments of Dermatology and Pathology, Boston University School of Medicine

Disclosure: Nothing to disclose.


Nauman Nisar, MD, Dermatopathologist, Mercy Medical Center, Sioux City, IA

Disclosure: Nothing to disclose.

Specialty Editors

Ponciano D Cruz Jr, MD, Professor and Vice-Chair, Paul R Bergstresser Chair, Department of Dermatology, University of Texas Southwestern Medical Center

Disclosure: RCTS Consulting fee Independent contractor; Mary Kay Cosmetics Honoraria Consulting; Galderma Grant/research funds Principal Investigator

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Auxillium Honoraria Consulting; Stiefel, a GSK company Honoraria Consulting; UpToDate Honoraria author/editor; JAMA Dermatology Honoraria Associate editor and intermittent author; Elsevier Royalty Book author/editor; Stock holdings in various trust accounts include some pharmaceutical companies and device makers I do not control these accounts, but have directed our managers to divest pharmaceutical stocks as is fiscally prudent I inherited these trust accounts

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Ackerman Academy of Dermatopathology, New York

Disclosure: Nothing to disclose.


  1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. Dec 20 1990;323(25):1729-35. [View Abstract]
  2. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. Jan 2004;9(1):29-33. [View Abstract]
  3. Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. Jul 2011;29(3):419-25, viii. [View Abstract]
  4. Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. Nov 2013;54(4):241-50. [View Abstract]
  5. Hertzberg MS, Schifter M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol. Feb 2000;63(2):105-6. [View Abstract]
  6. Martinez De Pablo MI, Iranzo P, Mascaro JM, Llambrich A, Baradad M, Herrero C. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol. 2005;85(3):233-5. [View Abstract]
  7. Tilakaratne W, Dissanayake M. Paraneoplastic pemphigus: a case report and review of literature. Oral Dis. Sep 2005;11(5):326-9. [View Abstract]
  8. Hung IJ, Lin JJ, Yang CP, Hsueh C. Paraneoplastic syndrome and intrathoracic Castleman disease. Pediatr Blood Cancer. Oct 15 2006;47(5):616-20. [View Abstract]
  9. Marzano AV, Vezzoli P, Mariotti F, Boneschi V, Caputo R, Berti E. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br J Dermatol. Jul 2005;153(1):214-5. [View Abstract]
  10. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. Oct 2005;141(10):1285-93. [View Abstract]
  11. Koch LH, Layton CJ, Pilichowska M, Stadecker MJ, Barak O. Paraneoplastic Pemphigus and Castleman's Disease in the Setting of Herpes Simplex Virus Infection. Pediatr Dermatol. Oct 20 2011;[View Abstract]
  12. Perera GK, Devereux S, Mufti G, Salisbury J, Creamer D. PNP with Waldenström's macroglobulinaemia. Clin Exp Dermatol. Jan 2005;30(1):27-9. [View Abstract]
  13. Wang J, Bu DF, Li T, et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol. Sep 2005;153(3):558-64. [View Abstract]
  14. Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N. Paraneoplastic pemphigus in patient infected with the human immunodeficiency virus. Clin Exp Dermatol. Jan 2014;39(1):83-5. [View Abstract]
  15. Eccersley LR, Hoffbrand AV, Rustin MH, McNamara CJ. Paraneoplastic pemphigus associated with systemic mastocytosis. Am J Hematol. May 27 2009;[View Abstract]
  16. Kennedy NA, Dawe S. Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement. Clin Exp Dermatol. Jul 2009;34(5):e130-3. [View Abstract]
  17. Kakurai M, Demitsu T, Iida E, et al. Coexistence of paraneoplastic pemphigus and bullous pemphigoid. J Eur Acad Dermatol Venereol. Aug 2009;23(8):962-4. [View Abstract]
  18. Ishii N, Hashimoto T. A case of paraneoplastic pemphigus who shifted to pemphigus vulgaris. J Eur Acad Dermatol Venereol. Mar 2008;22(3):374-5. [View Abstract]
  19. Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. Jan 2007;56(1):153-9. [View Abstract]
  20. Coelho S, Reis JP, Tellechea O, Figueiredo A, Black M. Paraneoplastic pemphigus with clinical features of lichen planus associated with low-grade B cell lymphoma. Int J Dermatol. May 2005;44(5):366-71. [View Abstract]
  21. Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. Oct 2012;148(10):1165-72. [View Abstract]
  22. Laforest C, Huilgol SC, Casson R, Selva D, Leibovitch I. Autoimmune bullous diseases: ocular manifestations and management. Drugs. 2005;65(13):1767-79. [View Abstract]
  23. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. Jul 1993;129(7):883-6. [View Abstract]
  24. Proby C, Fujii Y, Owaribe K, Nishikawa T, Amagai M. Human autoantibodies against HD1/plectin in paraneoplastic pemphigus. J Invest Dermatol. Feb 1999;112(2):153-6. [View Abstract]
  25. Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. Nov 2013;169(5):1016-24. [View Abstract]
  26. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. Mar 1995;32(3):441-7. [View Abstract]
  27. Bennett DD, Busick TL. Delayed detection of autoantibodies in paraneoplastic pemphigus. J Am Acad Dermatol. Dec 2007;57(6):1094-5. [View Abstract]
  28. Huang Y, Li J, Zhu X. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus. Arch Dermatol Res. Nov 2009;301(10):703-9. [View Abstract]
  29. Mouquet H, Drenovska K, Lartigue A, et al. Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay. Clin Immunol. Nov 2008;129(2):304-12. [View Abstract]
  30. Probst C, Schlumberger W, Stocker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. Sep 6 2009;[View Abstract]
  31. Barnadas MA, Curell R, Alomar A, Gelpi C. Paraneoplastic pemphigus with negative direct immunofluorescence in epidermis or mucosa but positive findings in adnexal structures. J Cutan Pathol. Jan 2009;36(1):34-8. [View Abstract]
  32. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. Oct 2011;29(4):607-12. [View Abstract]
  33. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. Aug 2007;34(8):503-11. [View Abstract]
  34. Barnadas M, Roe E, Brunet S, et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol. Jan 2006;20(1):69-74. [View Abstract]
  35. Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag. Feb 2009;5(1):1-7. [View Abstract]
  36. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. Aug 15 1998;102(4):775-82. [View Abstract]
  37. Hashimoto T. Immunopathology of paraneoplastic pemphigus. Clin Dermatol. Nov-Dec 2001;19(6):675-82. [View Abstract]
  38. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. Aug 1992;128(8):1091-5. [View Abstract]
  39. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. Oct 2000;43(4):619-26. [View Abstract]
  40. Leung CL, Liem RK, Parry DA, Green KJ. The plakin family. J Cell Sci. Oct 2001;114:3409-10. [View Abstract]
  41. Li J, Bu DF, Huang YC, Zhu XJ. Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus. Chin Med J (Engl). Mar 5 2009;122(5):486-95. [View Abstract]
  42. Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. Aug 1998;111(2):308-13. [View Abstract]
  43. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. Jul 1993;11(3):473-81. [View Abstract]
  44. Ruhrberg C, Watt FM. The plakin family: versatile organizers of cytoskeletal architecture. Curr Opin Genet Dev. Jun 1997;7(3):392-7. [View Abstract]
  45. Stone SP, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol. May-Jun 2005;23(3):301-6. [View Abstract]
  46. Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol. Feb 2005;46(1):1-8; quiz 9-10. [View Abstract]
  47. Wakahara M, Kiyohara T, Kumakiri M, et al. Paraneoplastic pemphigus with widespread mucosal involvement. Acta Derm Venereol. 2005;85(6):530-2. [View Abstract]

Direct immunofluorescence microscopy performed on epithelial biopsy specimen obtained from a patient with pemphigus vulgaris detects immunoglobulin G deposits at the epithelial cell surfaces.

Direct immunofluorescence microscopy performed on epithelial biopsy specimen obtained from a patient with pemphigus vulgaris detects immunoglobulin G deposits at the epithelial cell surfaces.

Direct immunofluorescence microscopy performed on epithelial biopsy specimen obtained from a patient with pemphigus vulgaris detects immunoglobulin G deposits at the epithelial cell surfaces.